MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Globus Medical Cost of Revenue 2011-2026 | GMED
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Globus Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 958 M | 1.04 B | 548 M | 264 M | 239 M | 217 M | 180 M | 159 M | 150 M | 135 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.04 B | 135 M | 389 M |
Quarterly Cost of Revenue Globus Medical
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 234 M | 253 M | 249 M | 195 M | 271 M | 260 M | 241 M | 135 M | 76.5 M | 70.8 M | - | 65.5 M | 68.5 M | 59.2 M | - | 58.6 M | 63.8 M | 55 M | - | 57.1 M | 50.6 M | 48.9 M | - | 45.4 M | 44 M | 41.8 M | - | 37.8 M | 37.6 M | 38 M | - | 36.8 M | 37.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 271 M | 36.8 M | 105 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.1 | -4.87 % | $ 154 M |  France |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K |  USA |
 |
Axonics Modulation Technologies
AXNX
|
91.8 M | - | - | $ 3.31 B | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | -0.96 % | $ 17.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.5 | -2.71 % | $ 326 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 7.83 | -2.85 % | $ 1.18 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.86 | -3.14 % | $ 70.1 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Helius Medical Technologies
HSDT
|
500 K | $ 2.24 | -2.61 % | $ 49.4 M | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.54 | -1.91 % | $ 62.7 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.49 | 6.42 % | $ 30.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.55 | -1.96 % | $ 412 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.91 | 0.74 % | $ 391 M | USA |
 |
Myomo
MYO
|
14 M | $ 1.0 | -2.91 % | $ 41.9 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 73.9 | -2.02 % | $ 4.03 B |  Britain |
 |
Orthofix Medical
OFIX
|
256 M | $ 9.32 | -4.61 % | $ 369 M |  Curacao |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 3.61 | -1.63 % | $ 534 M | USA |
 |
Profound Medical Corp.
PROF
|
4.7 M | $ 6.87 | 1.48 % | $ 208 M | Canada |
 |
Electromed
ELMD
|
14 M | $ 38.26 | 0.21 % | $ 323 M | USA |
 |
Butterfly Network
BFLY
|
51.9 M | $ 4.68 | 3.08 % | $ 1.16 B | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.29 | -5.76 % | $ 6.35 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 146.01 | -5.07 % | $ 10.3 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 35.48 | -1.61 % | $ 1.1 B | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 42.22 | 0.33 % | $ 1.24 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 88.97 | -1.3 % | $ 3.09 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 86.51 | -1.18 % | $ 50.6 B | USA |
 |
TransMedics Group
TMDX
|
243 M | $ 70.15 | -0.44 % | $ 2.38 B | USA |